Benzinga · Feb 25, 2026
EN
NASDAQ · ENVB
Enveric Biosciences, Inc.
Healthcare · Biotechnology
$1.52
Up+$0.03 (+1.67%)
Updated Oct 9, 2026, 4:01 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.25M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.17 – $13.25
- Volume
- 64.87K
- Avg. volume
- 85.35K
Price performance · ENVB
ENVB price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
ENVB closed at $1.52 after 21 trading sessions, up 4.11% for the selected period.
- Last close
- $1.52
- Period change
- +4.11%
- Period low
- $1.42
- Period high
- $1.62
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $1.47 | $1.5309 | $1.46 | $1.52 | 64.87K |
| Oct 7, 2026 | $1.45 | $1.5099 | $1.45 | $1.495 | 41.37K |
| Oct 6, 2026 | $1.53 | $1.53 | $1.43 | $1.47 | 50.96K |
| Oct 5, 2026 | $1.46 | $1.5299 | $1.45 | $1.51 | 54.33K |
| Oct 2, 2026 | $1.51 | $1.53 | $1.46 | $1.48 | 72.98K |
| Oct 1, 2026 | $1.455 | $1.48 | $1.41 | $1.46 | 83.63K |
| Sep 30, 2026 | $1.44 | $1.53 | $1.421 | $1.485 | 57.07K |
| Sep 29, 2026 | $1.46 | $1.4799 | $1.4225 | $1.45 | 46.47K |
| Sep 28, 2026 | $1.51 | $1.56 | $1.4504 | $1.47 | 63.61K |
| Sep 25, 2026 | $1.5222 | $1.53 | $1.4801 | $1.50 | 38.23K |
| Sep 24, 2026 | $1.57 | $1.58 | $1.4783 | $1.545 | 85.02K |
| Sep 23, 2026 | $1.5758 | $1.60 | $1.52 | $1.565 | 114.95K |
| Sep 22, 2026 | $1.54 | $1.6077 | $1.52 | $1.54 | 47.39K |
| Sep 21, 2026 | $1.64 | $1.6486 | $1.55 | $1.56 | 52.42K |
| Sep 18, 2026 | $1.62 | $1.6494 | $1.5194 | $1.62 | 158.57K |
| Sep 17, 2026 | $1.4933 | $1.64 | $1.4892 | $1.59 | 172.69K |
| Sep 16, 2026 | $1.45 | $1.54 | $1.45 | $1.49 | 52.12K |
| Sep 15, 2026 | $1.47 | $1.53 | $1.44 | $1.46 | 75.32K |
| Sep 14, 2026 | $1.4231 | $1.5378 | $1.4098 | $1.48 | 104.93K |
| Sep 11, 2026 | $1.45 | $1.48 | $1.42 | $1.42 | 38.75K |
| Sep 10, 2026 | $1.45 | $1.46 | $1.42 | $1.46 | 11.47K |
Latest ENVB news
The latest Smart Investors Daily articles mentioning ENVB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ENVB research
Overview
Company profile and research snapshot.
Company profile
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 6, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 1, 2022 | Alliance Global Partners | Buy | — |
| Mar 8, 2022 | Aegis Capital | Hold | — |
| Jul 8, 2021 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested
Gilgamesh withdraws patent challenge against Enveric, leaving the key psilocybin patent uncontested.
Benzinga · Feb 25, 2026
Enveric Biosciences Announces Withdrawal Of Petition Against Patent; Co Says There Are 'No Remaining Challenges' Pending Against Patent
Benzinga · Feb 19, 2026
Enveric Biosciences shares are trading higher after the company announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
